Business
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical
About this update from Alpha Cognition Inc.
[{"type":"text","content":" VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--\nAlpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition’s commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer’s disease.\n\n\nMs. Pesa brings 25 years of pharmaceutical commercial leadership to Alpha Cognition. Jen has successfully launched 12 products across 13 therapeutic areas, including neurology, psychiatry, and in multiple geriatric markets. With 14 years dedicated to long-term care (LTC), she has a deep understanding of this complex segment and a proven track record in building strategies that improve patient outcomes while enhancing healthcare delivery. Her expertise in driving cross-functional collaboration across marketing, market access, and sales operations will be instrumental in establishing the commercial success of ZUNVEYL.\n\n\nMr. Kelly brings over 30 years of experience in roles of increasing responsibility in the pharmaceutical industry with Bristol-Myers Squibb, Daiichi Sankyo (DSI), and most recently Arbor Pharmaceuticals. He has successfully developed and implemented market access launch strategies, while growing numerous products in the CNS and 505(B)(2) space. Additionally, he has led strategic account management and contract negotiations with key payers, including Medicare, by delivering value-added solutions and services to customers and patients.\n\n\nMr. Fernandez is a commercial strategy executive with over 17 years of experience driving growth and innovation in the pharmaceutical and biotechnology industries. He has played a pivotal role in the commercialization and launch of six pharmaceutical products, delivering measurable outcomes for patients, providers, and stakeholders. As Chief Analytics Officer at Fingerpaint Group, Rommel led the integration of advanced analytics and generative AI into business operations...